Friday, 14 Dec 2018

You are here

First FDA Approved Drug for HLH

The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.

Emapalumab (Gamifant), manufactured by Novimmune SA, may be used in all patients (including newborns and older children) "who have refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy," the FDA said.

HLH is a very rare condition in which immune cells go into overdrive, releasing pro-inflammatory molecules that damage many of the body's organs. It can be inherited (primary HLH), with various genes implicated, but can also be secondary to other conditions. In the primary form, symptoms typically develop shortly after birth. Allogeneic hematopoietic stem cell transplant is the most effective treatment and can result in cure. Other treatments include chemotherapy and immunotherapy, according to the National Institutes of Health.

Emapalumab's efficacy was demonstrated in a 27-patient pediatric trial, with 70% able to proceed to stem cell transplant, the FDA said.

The agency cautioned that patients receiving the drug should not receive live-pathogen vaccines and should be tested for latent tuberculosis before starting treatment. Infections are a concern with the drug and clinicians should actively monitor patients for them.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks

Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks.

FDA Approves Biosimilar Rituximab for NHL, not RA

The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.